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Objective. Survival in patients with systemic scle-
rosis (SSc)–associated pulmonary hypertension (PH)
and interstitial lung disease (ILD) is poor. Evidence
supporting the efficacy of aggressive pulmonary arterial
hypertension (PAH)–targeted therapy in this popula-
tion is limited. The aim of this study was to investigate
transplant-free survival in patients with isolated SSc-
related PAH or SSc-related PH-ILD who were treated
with aggressive PAH-targeted therapy.
Methods. SSc patients with right-sided heart
catheterization (RHC)–diagnosed precapillary PH
(mean pulmonary artery pressure >25 mm Hg, pulmo-
nary capillary wedge pressure <15 mm Hg, and pulmo-
nary vascular resistance >240 dynes  second/cm5)
were included. Patients were classified as having ILD
based on review of high-resolution computed tomo-
graphy (CT) chest imaging and spirometry. The
Kaplan-Meier method was applied and Cox propor-
tional hazards models were constructed to analyze
survival and identify predictive variables.
Results. Of 99 patients with SSc-related precap-
illary PH, 28% had SSc-related PAH and 72% had
SSc-related PH-ILD. The 1- and 2-year survival esti-
mates were, respectively, 72% and 59% in the SSc-
related PH-ILD group versus 82% and 66% in the
SSc-related PAH group (P  0.5). Within 6 months of
the diagnostic RHC, 24% of all patients were started on
prostanoid therapy; an additional 24% were started on
prostanoid therapy after 6 months. In the multivariate
model, male sex (hazard ratio [HR] 0.7, P  0.01) and
prostanoid therapy initiation within 6 months of the
RHC (HR 1.4, P  0.01) were the only factors signifi-
cantly associated with transplant-free survival, after
accounting for the presence of ILD and severity of PH.
Conclusion. In this study, survival of patients
with SSc-related PH-ILD was modestly improved rela-
tive to historical series. While these findings may not be
generalizable, improved survival may be due partly to
aggressive PAH-targeted therapy.
Pulmonary arterial hypertension (PAH) is a lead-
ing cause of death in patients with systemic sclerosis
(SSc). Although survival in patients with SSc-related
PAH may appear improved in the current era of PAH-
targeted therapy, this may be confounded by early
screening and diagnosis (1), lead time bias (2), and
predominant use of cohorts of patients with prevalent
disease (3).
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Compared with isolated SSc-related PAH, SSc
patients with both pulmonary hypertension (PH) and
interstitial lung disease (ILD) have an increased risk of
death (4–6). Despite use of PAH-targeted therapy,
SSc-related PH-ILD has a 3-year survival rate of 21%
(6). However, aggressive PAH-targeted therapy, defined
as either combination therapy or the use of parenteral
prostanoid, is underutilized in patients with SSc-related
PAH and SSc-related PH-ILD as compared with pa-
tients with idiopathic PAH (7). At our center, the
threshold to introduce aggressive PAH-targeted therapy
for SSc-related PAH is perhaps lower than that in usual
practice (8) and is not influenced by the extent of
concurrent ILD. The purpose of the present study was to
assess survival rates and prognostic variables in patients
with SSc-related PAH and SSc-related PH-ILD, and to
determine whether aggressive PAH-targeted therapy
improves survival, particularly in patients with SSc-
related PH-ILD.
PATIENTS AND METHODS
Patient population. This was a retrospective cohort
study of patients with SSc-related PAH and SSc-related PH-
ILD, who were all treated with PAH-targeted therapy. The
Institutional Review Board at the University of California, Los
Angeles (UCLA) approved this study (no. 12-000738).
Eligibility criteria. Criteria for study eligibility were as
follows: 1) 18 years of age, 2) diagnosed as having SSc (9), 3)
referred to the UCLA PH clinic between January 1, 2000 and
January 1, 2012, and 4) diagnosed as having precapillary PH
(defined as a mean pulmonary arterial pressure [PAP] 25
mm Hg, pulmonary capillary wedge pressure [PCWP]15 mm
Hg, and pulmonary vascular resistance [PVR] 240 dynes 
seconds/cm5, in the absence of other causes of PH) (10).
Baseline assessments. The date of the diagnostic right-
sided heart catheterization (RHC) served as the baseline date,
and all assessments were independently extracted in duplicate
from electronic medical records. The extent of missing data
was minimized by rigorous chart extraction, including extract-
ing records from other institutions/clinics. Duration of SSc was
based on the difference between the dates of the diagnostic
RHC and SSc onset (defined as the date a rheumatologist
diagnosed the patient as having SSc). Relevant laboratory data
were extracted if tests were performed within 6 months of the
diagnostic RHC.
Selected comorbidities were recorded, including type 1
and type 2 diabetes requiring insulin, systemic hypertension,
coronary artery disease (defined as prior documented myocar-
dial infarction, typical angina, coronary revascularization, or
coronary artery stenosis of 50% on angiography), and renal
insufficiency as determined by the Modification of Diet in
Renal Disease (MDRD) estimated glomerular filtration rate
(GFR).
Data on supplemental oxygen use, pulmonary function
test results, and 6-minute walk distance were extracted if
collected within 6 months of the diagnostic RHC. Oxygen
saturation data related to the 6-minute walk test were not
extracted due to a lack of systematic assessment and/or use of
temporal pulse oximetry.
Primary predictors. Interstitial lung disease. The diag-
nosis of ILD was primarily based on review of high-resolution
computed tomography (CT) imaging of the chest obtained
within 6 months of the diagnostic RHC. Patients were classi-
fied as having significant ILD if the total disease extent was
30%; when high-resolution CT yielded indeterminate results
(i.e., disease extent was 10–30%), a forced vital capacity (FVC)
of 70% of the predicted value was used to classify patients as
having ILD (11). This valid ILD staging system has had
prognostic significance in prior survival analyses of patients
with SSc ILD (6). A pulmonologist (Rajan Saggar) reviewed
the high-resolution CT images under blinded conditions to
determine disease presence/extent. Patients were classified as
not having significant ILD if the extent of the disease was
10% on high-resolution CT or if the FVC was 70%.
High-resolution CT images were unavailable for 11 patients; in
all of those patients, results of radiology reports confirmed the
presence of diffuse ILD (i.e., 30%). As such, these 11
patients were classified as having ILD.
Aggressive PAH-targeted therapy. Data on PAH-
targeted therapy were extracted by reviewing the medication
portion of every progress note for all patients until the censor
date. Aggressive PAH-targeted therapy was defined a priori as
the use of a prostanoid (oral, inhaled, or parenteral), and
prostanoid initiation within 6 months of the diagnostic RHC
(12). This 6-month threshold was selected based on the
following: 1) the clinical experience of the authors, 2) the time
cutoff reported in a study on the long-term survival experience
of patients with SSc-related PAH in the setting of PH-targeted
therapy with epoprostenol (12), and 3) the recognition that
oral therapies are often considered first-line PH-targeted
therapy in the population of patients with SSc-related PH-ILD
(6) and that parenteral therapies often require a reasonable
amount of time for insurance authorization and actual initia-
tion.
Prostanoids were administered via the following
routes: parenteral (n  33 patients), inhaled (n  7 patients),
and oral (n  4 patients). Treprostinil was used in all patients
who received parenteral prostanoids. For patients with SSc-
related PH-ILD receiving prostanoids, 25 (74%) were receiv-
ing parenteral prostanoid, while 5 (15%) were receiving in-
haled prostanoid, and 4 (12%) were receiving oral prostanoid.
The median maximum dosage achieved in the parenteral
prostanoid cohort was 54 ng/kg/minute (interquartile range
[IQR] 42.0–82.3).
Outcome measures. The primary outcome measure
was transplant-free survival. Dates of death and lung trans-
plantation were recorded until the censor date of June 1, 2012.
Mortality data were obtained from the electronic medical
record, National Death Index, Social Security Death Index, as
well as via online obituaries. If a patient was lost to followup,
the date of last contact at UCLA was entered as the censor
date.
Secondary outcome measures included 1) time to
initiation of prostanoid therapy from the diagnostic RHC, 2)
differences in baseline hemodynamics and pulmonary function
test results between patients who received early (6 months
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from the RHC) versus late (6 months from the RHC) versus
no prostanoid use, and 3) maximum dosage of parenteral
prostanoid administered.
Statistical analysis. Analyses were performed using
JMP 10.0 for Macintosh. Continuous parametric data were
expressed as the mean  SD, and continuous nonparametric
data were expressed as the median and IQR. Between-group
comparisons were conducted using independent t-tests for
continuous parametric data, Wilcoxon’s rank sum test for
continuous nonparametric data, and chi-square tests and Fish-
er’s exact tests for proportions. The Kaplan-Meier method was
used for the survival analysis, and the log rank test was used to
compare groups. Multivariate Cox proportional hazards mod-
eling was performed to determine the variables associated with
transplant-free survival.
RESULTS
Patient characteristics. Among the 251 patients
with SSc who underwent RHC during the study period,
99 met RHC criteria for either SSc-related PAH (n 
28) or SSc-related PH-ILD (n 71) (Figure 1). Of these
99 patients, the majority (71%) underwent their diag-
nostic RHC at UCLA. For the remaining patients, the
median time from the outside RHC to the initial PH
clinic consultation at UCLA was 3.5 months (IQR
1.4–18.5 months).
Baseline demographic characteristics and comor-
bidities were similar among patients with SSc-related
PAH and those with SSc-related PH-ILD, with the
exception of sex and estimated GFR (Table 1). The
majority of patients in both groups had limited cutane-
ous SSc, with a median disease duration of 7 years. The
presence of diabetes mellitus requiring insulin was rare
(7% in both groups), as was status as a current smoker (3
patients with SSc-related PAH and 1 patient with SSc-
related PH-ILD). More patients in the SSc-related PH-
ILD group as compared with the SSc-related PAH
group were receiving low-dose prednisone (48% versus
21%, respectively; P  0.02) and immunosuppressive
agents other than prednisone (39% versus 21%, respec-
tively; P  0.07).
Hemodynamics and pulmonary function. Base-
line systemic and pulmonary hemodynamics, 6-minute
walk distance, and need for supplemental oxygen were
Figure 1. Flow chart of the selection of systemic sclerosis (SSc) patients for study inclusion. RHC  right-sided heart catheterization; mPAP 
mean pulmonary artery pressure; PCWP  pulmonary capillary wedge pressure; PVR  pulmonary vascular resistance; HRCT  high-resolution
computed tomography; PH  pulmonary hypertension; ILD  interstitial lung disease; PAH  pulmonary arterial hypertension.
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similar among patients with SSc-related PAH and pa-
tients with SSc-related PH-ILD (Table 2). Forty-nine
percent of all SSc patients had severe precapillary PH,
defined as a mean PAP 40 mm Hg (54% of patients
with SSc-related PAH and 48% of patients with SSc-
related PH-ILD). Patients with SSc-related PH-ILD had
significantly lower FVC (% predicted) and diffusing
capacity for carbon monoxide (DLCO) (% predicted) as
compared with SSc-related PAH patients; however, the
mean FVC/DLCO was identical in both groups.
PAH-targeted therapies. Data on PAH-specific
therapy were available for 91 patients (92% of the
patient cohort) (Table 3). None of the patients were
receiving aggressive PAH-targeted therapy (i.e., combi-
nation therapy or prostanoid) during the initial PH consul-
tation at the UCLA clinic. For the majority of patients,
initial PAH therapy included a phosphodiesterase 5
(PDE-5) inhibitor (43%) or an endothelin receptor
antagonist (45%). Over 50% of the entire cohort was
treated with at least 2 PH-specific therapies during the
study period. Twenty-four percent of patients (1 patient
with SSc-related PAH [4% of the group] and 21 patients
with SSc-related PH-ILD [32% of the group]) started on
prostanoid 6 months after the RHC (early prostanoid
initiation), while an additional 24% (9 patients with
SSc-related PAH [36% of the group] and 13 with
SSc-related PH-ILD [20% of the group]) started on
prostanoid 6 months after the diagnostic RHC (late
prostanoid initiation). The median time from RHC to
initiation of a prostanoid was 0.5 months (IQR 0–2.9
months) for early prostanoid initiators and 26.4 months
(IQR 10.9–40.4 months) for late prostanoid initiators.
Early versus late prostanoid initiation. Pulmo-
nary hemodynamics. The mean PAP was significantly
lower among patients who never received prostanoid
therapy versus patients who were started on prostanoid
therapy early or late, with a mean  SD of 38.1  9.0 in
those who never received prostanoid, 45.0  10.2 in
those who received the drug 6 months after the RHC,
and 44.1  11.7 in those who received prostanoid 6
months after the RHC (P 0.03). The same was true for
the PVR index, with a median of 768.1 (IQR 511.3–
1,124.9) in those who never received prostanoid therapy,
1,184.8 (IQR 643.5–1,584.4) in those who received the
drug early, and 1,032.1 (IQR 619.7–1,404.1) in those
who received the drug late (P  0.03). There was no
difference in the mean PAP or median PVR index
between patients who started on a prostanoid early
versus late.
Pulmonary function. Patients who were started on
treatment with a prostanoid early had a trend toward a
lower mean FVC (% predicted) (mean  SD 56.3 
20.0) as compared with patients who were started on
prostanoid therapy late (71.0  13.8) and patients who
never received prostanoid therapy (62.2  23.3) (P 
0.09). There was no difference in mean DLco (%
predicted) between the 3 groups.
Transplant-free survival. Followup time was sim-
ilar between the 2 groups, with a mean  SD of 30.9 
29.7 months and a median of 19.8 months (IQR 6.3–50)
among patients with SSc-related PAH and a mean SD
of 26.8  24.3 months and a median of 18.6 months
(IQR 8.1–37.7) among patients with SSc-related PH-
ILD. Only 3 patients were lost to followup (1 patient
with SSc-related PAH and 2 patients with SSc-related
PH-ILD). During the study, 41 patients (41%) died (15
patients [54%] in the SSc-related PAH group and 26
patients [37%] in the SSc-related PH-ILD group), and
14 patients (14%) underwent lung transplantation (all 14
had SSc-related PH-ILD). The 1-, 2-, and 3-year survival
estimates were, respectively, 82%, 66%, and 60% among
patients with SSc-related PAH and 72%, 59%, and 50%
Table 1. Baseline characteristics of the study population*
SSc-related PAH
(n  28)
SSc-related PH-ILD
(n  71)
Age, mean  SD years 59.7  12.8 54.5 12.1
Sex, female 26 (92.9)† 50 (70.4)
Ethnicity‡
White 18 (64.3) 37 (52.1)
African American 3 (10.7) 9 (12.7)
Hispanic 5 (17.9) 16 (22.5)
Asian 1 (3.6) 9 (12.7)
Other 1 (3.6) 0
SSc type§
Limited cutaneous 20 (71.4) 50 (70.4)
Diffuse cutaneous 8 (28.6) 21 (29.6)
SSc duration, median (IQR)
years
7.0 (2.8–13.9) 7.3 (2.7–13.2)
Coronary artery disease 4 (14.3) 4 (5.6)
Systemic hypertension 9 (32.1) 16 (22.5)
Hgb, mean  SD mg/dl¶ 12.3  1.6 12.5 1.9
MDRD estimated GFR,
median (IQR) ml/minute/
1.73 m2
58.3 (53.1–77.4)# 76.4 (59.1–105.0)
* Except where indicated otherwise, values are the number (%).
IQR  interquartile range; Hgb  hemoglobin; MDRD  Modifica-
tion of Diet in Renal Disease; GFR  glomerular filtration rate.
† P  0.02 versus systemic sclerosis (SSc)–related pulmonary hyper-
tension (PH) complicated by interstitial lung disease (ILD).
‡ Due to low numbers in subgroups, chi-square test was not per-
formed.
§ Information on SSc type was missing for 1 patient in the SSc-related
PH-ILD group; for analysis, the patient was classified as having limited
cutaneous SSc.
¶ Data available on 26 patients with SSc-related pulmonary arterial
hypertension (PAH) and 68 patients with SSc-related PH-ILD.
# P  0.01 versus SSc-related PH-ILD.
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among patients with SSc-related PH-ILD (Figure 2).
There were no differences in transplant-free survival
between patients with SSc-related PAH and those with
SSc-related PH-ILD (log rank P  0.5).
To minimize the possibility of lead time bias, we
performed a second survival analysis that excluded 13
patients who had their first pulmonary consultation at
UCLA 3 months after their diagnostic RHC was
performed at a center other than UCLA. The results of
this survival analysis did not differ from those of the
overall analysis: there was no difference in survival
between the remaining SSc-related PAH patients (n 
22) and SSc-related PH-ILD patients (n  64) (log rank
P  0.9). The 1-, 2-, 3- year survival estimates were,
respectively, 76%, 63%, and 55% among patients with
SSc-related PAH and 70%, 60%, 49% among patients
with SSc-related PH-ILD. In addition, to address the
issue of a possible immortality bias, we explored whether
patients who were referred to UCLA after their outside
diagnostic RHC (n  29 patients) disproportionately
received early prostanoid therapy. We found that only 3
of these patients received early prostanoid therapy (12
received late prostanoid therapy, 12 received no prosta-
noid therapy, and 2 patients had missing medication
data).
Factors associated with transplant-free survival.
To avoid overfitting (i.e., including too many variables in
the model for the number of outcome events), the
following initial covariates were entered into the model:
ILD (i.e., extent of ILD based on the scoring system
described by Goh et al [11]; categorical variable), PVR
index (in dynes  seconds/cm5/m2; continuous variable),
prostanoid use (early use [i.e., within 6 months of RHC],
late use [i.e., 6 months after RHC], or no prostanoid use;
categorical variable). The first 2 variables were included
in the model given their independent association with
survival in SSc (5). In this initial model, only early
prostanoid use was significantly associated with im-
proved survival (hazard ratio [HR] 1.3, P  0.006).
The following covariates, which in prior studies
were associated with survival in patients with SSc-related
ILD, were added to the model sequentially and retained
if significantly associated with the outcome: age (years),
sex, African American, SSc type (diffuse cutaneous or
limited cutaneous), SSc duration (years), hemoglobin
level (gm/dl), MDRD estimated GFR, supplemental
oxygen at diagnosis, use of prednisone or other immu-
Table 2. Baseline hemodynamic and pulmonary function features of the study population*
SSc-related PAH (n  28) SSc-related PH-ILD (n  71)
Hemodynamics
SBP, mm Hg 124.3 23.8 120.8  21.3
DBP, mm Hg 71.6  13.6 69.7  11.8
Heart rate, bpm 87.7  12.3 87.0 16.0
Mean PAP, mm Hg 43.4  12.5 39.7  9.4
PAWP, mm Hg 9.9 3.3 9.6  3.5
PVR index, median (IQR) dynes  seconds/cm5 1,064.2 (551.7–1,300) 832.0 (600–1,280)
RAP, mm Hg 9.8  6.8 7.4 4.8
Cardiac output 4.6 1.3 4.6  1.2
Cardiac index 2.8 0.7 (n  21) 2.8 0.7 (n  57)
Use of supplemental oxygen, no. (%) 14 (53.8) (n  26) 27 (39.1) (n  69)
6-minute walk distance, median (IQR) meters 279 (132.5–414) (n 18) 275 (121.5–346.5) (n 48)
FVC, % predicted 82.7  15.2 (n  21)† 56.0 18.2 (n  59)
DLCOadj for Hgb, % predicted 50.6  13.6 (n  18)‡ 34.4  13.4 (n  56)
FVC/DLCO ratio 1.8  0.5 (n  18) 1.8  0.7 (n  55)
* Except where indicated otherwise, values are the mean  SD. SBP  systolic blood pressure; DBP  diastolic blood
pressure; bpm  beats per minute; PAP  pulmonary artery pressure; PAWP  pulmonary capillary wedge pressure;
PVR  pulmonary vascular resistance; RAP  right atrial pressure; FVC  forced vital capacity; DLCOadj  diffusing
capacity for carbon monoxide adjusted (see Table 1 for other definitions).
† P  0.0001 versus SSc-related PH-ILD.
‡ P  0.0001 versus SSc-related PH-ILD.
Table 3. Initial PH medication taken during the study*
SSc-related PAH
(n  25)
SSc-related
PH-ILD
(n  66)
Phosphodiesterase 5 inhibitor 13 (52.0) 26 (39.4)
Endothelin receptor antagonist 11 (44.0) 30 (45.5)
Prostanoid 0 7 (10.6)
Phosphodiesterase 5 inhibitor
and endothelin receptor
antagonist
1 (4.0) 2 (3.0)
Phosphodiesterase 5 inhibitor
and prostanoid
0 1 (1.5)
* Values are the number (%). See Table 1 for definitions.
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nosuppressive agent (yes or no). Among these additional
covariates, only sex was significantly associated with the
outcome and included in the final model with the initial
covariates (Table 4). After accounting for sex, PVR
index data, and ILD status, early prostanoid use re-
mained significantly associated with improved survival
(HR 1.4, P  0.01).
DISCUSSION
We evaluated transplant-free survival rates and
associated prognostic factors among patients with SSc-
related PAH and SSc-related PH-ILD, in the setting of
rigorous phenotyping for degree of ILD and precapillary
PH, as well as aggressive PAH-targeted therapy, where
nearly half of all patients received prostanoid therapy.
The results reported herein demonstrate similar survival
rates among patients with SSc-related PH-ILD and
SSc-related PAH. Of the baseline variables, aggressive
PAH-targeted therapy (i.e., prostanoid initiation within
6 months of the diagnostic RHC) was a predictor of
improved transplant-free survival, while the presence of
ILD was not a significant factor.
Compared with patients with SSc-related PAH,
patients with SSc-related PH-ILD historically have infe-
rior survival rates, with an estimated 3-year survival rate
of 21–35% in prior series (4,6,13). Despite the fact that
heterogeneous methodology was used to define ILD in
some of these prior studies, the present cohort of
patients with SSc-related PH-ILD had a 3-year survival
Figure 2. Kaplan-Meier survival curves demonstrating no difference in survival between patients with systemic sclerosis (SSc)–related pulmonary
arterial hypertension (PAH) alone (black line) and patients with SSc-related pulmonary hypertension (PH) complicated by interstitial lung disease
(ILD) (gray line) (P  0.5 by log rank test).
Table 4. Multivariate model of factors associated with transplant-
free survival in patients with SSc-related PH*
Variable
Hazard
ratio
Standard
error P
ILD (referent: no significant ILD) 0.9 0.2 0.6
Prostanoid initiation (referent: no
prostanoid therapy)
0.01
6 months after RHC 1.4 0.2
6 months after RHC 0.5 0.3
Sex (referent: women) 0.7 0.2 0.01
PVR index 1.0 0.0003 0.04
* RHC  right heart catheterization; PVR  pulmonary vascular
resistance (see Table 1 for other definitions).
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rate of 50%. While multiple factors may explain this
relatively improved survival rate, our cohort has similar
hemodynamic and pulmonary function profiles com-
pared with the aforementioned cohorts (4,6).
One possible explanation for improved survival is
our aggressive use of PAH-targeted therapy, specifically
the early use of prostanoid therapy. In general, prosta-
noid therapy is underutilized in PAH (14), particularly in
the population of patients with SSc-related PAH (7).
Nevertheless, parenteral prostanoid is considered opti-
mal therapy for patients with advanced/progressive PAH
who are at higher risk of death (15), and it may confer a
survival advantage when compared with oral PAH-
targeted therapies (16).
Prostanoid is likely further restricted as a treat-
ment for SSc-related PH-ILD due to the possibility of
ventilation/perfusion mismatch–induced hypoxemia
(17). This concern is reflected in reduced prostanoid use
(between 9% and 17%) in prior SSc-related PH-ILD
cohorts (5,6,18). In contrast, approximately half of the
present SSc-related PH-ILD cohort received prostanoid
therapy during the study period. Despite the gas ex-
change concerns, SSc-related PH-ILD may in fact be the
ideal phenotype for prostanoid therapy given the often
severely advanced and progressive pulmonary vascular
disease evident at diagnosis (including World Health
Organization [WHO] functional class III or IV symp-
tomatology [6], baseline oxygen requirements greater
than those required in SSc-related PAH [5], and increas-
ing oxygen requirements over time [6]).
In addition, when a parenteral prostanoid is
administered, suboptimal dosing (40 ng/kg/minute for
infusions of treprostinil) may affect its efficacy and has
been independently associated with poor survival in
patients with WHO Group I PAH (19), and may also
contribute to the modest outcomes observed in prior
SSc-related PAH cohorts that used epoprostenol
(12,20). In our study, 75% of patients received a maxi-
mum dose above 40 ng/kg/minute, which was the favor-
able prognostic threshold reported by Benza and col-
leagues (19). Cautious use of prostanoids may have a
therapeutic role in the setting of pulmonary venoocclu-
sive disease (PVOD)–like lesions (21), which appear to
be a distinguishing feature of the pulmonary vasculopa-
thology of SSc-related PAH (22) and may be increased
in the setting of superimposed ILD (23). While patients
in the present study were not specifically assessed for
pathologic evidence of PVOD, we did not observe
clinical worsening clearly related to initiation of PAH-
targeted therapy that may have suggested underlying
PVOD.
However, given that this was a retrospective
study, there may be unexamined or unidentified factors
that favorably affect survival (i.e., greater family support,
superior insight into their condition, or determination to
overcome their disease), which differed between pa-
tients who received early prostanoid therapy compared
with the reference group of patients who received no
prostanoid therapy. However, the baseline hemody-
namic and pulmonary function parameters were signifi-
cantly worse in patients who received early prostanoid
therapy compared with the reference group; thus, it is
possible that the patients who received early prostanoid
therapy had a potential survival disadvantage at base-
line. Nevertheless, the implication that early prostanoid
use is independently associated with improved survival
in SSc-related PH is hypothesis-generating only and
requires confirmation in a prospective, randomized con-
trolled trial.
The multivariate model also indicated that late
prostanoid use portends a survival disadvantage. Given
that patients who received late prostanoid therapy had
worse baseline hemodynamics compared with patients
who never received prostanoid therapy, this survival
disadvantage is unlikely to be a result of late prostanoid
administration and more realistically, a reflection of the
advanced illness in this subset of patients receiving
prostanoid late in the course of the disease. This inter-
pretation is consistent with the results of a recent study,
which demonstrated that delayed and urgent prostanoid
initiation was associated with increased mortality in
patients with PAH (24). Overall, the present findings
suggest that there may be a finite, early window of
opportunity to possibly improve survival rates in patients
with SSc-related PAH and SSc-related PH-ILD using
prostanoid therapy.
In addition to early prostanoid use, male sex was
independently associated with survival in the multivari-
ate model. Although prior studies have shown that male
sex 1) is a predictor of poor survival in SSc (without lung
involvement) (25) and SSc-related PAH (13,26), 2) is a
predictor of the development of severe ILD (without
associated PH) (27), and 3) may be overrepresented in
SSc-related PH-ILD (versus SSc-related PAH) (18), our
study is the first to suggest that male sex is an indepen-
dent predictor of poor survival in the setting of well-
characterized SSc-related PH-ILD. In addition, the
PVR index has been previously reported by Mathai and
coworkers (5) as a predictor of mortality in SSc-related
PH-ILD; however, the hazard ratio (1.05) was similar to
that in our study (1.00). Other factors previously re-
ported as being independently associated with survival in
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SSc-related PH-ILD were either not associated with
survival in our study (i.e., MDRD estimated GFR [6]) or
were not assessed due to significant missing data (i.e.,
pericardial effusion [13], diffusing capacity [13], and
worsening oxygenation [6]).
Interestingly, the present study demonstrated
that significant ILD was not an independent risk factor
for death or need for transplant in patients with SSc-
related PH, in contrast to prior studies, which employed
the same methodology to define significant ILD (11,28).
In addition, there was no difference in transplant-free
survival in patients with or without ILD. While most of
the ILD patients had established ILD of 2 years’
duration, these results suggest that early prostanoid
therapy may be effective in patients with SSc-related
PH-ILD.
The present study has several strengths. First, 2
study physicians (Rajeev Saggar and Rajan Saggar)
performed the majority of the RHCs, thereby improving
reliability. Second, a single investigator (Rajan Saggar)
used a validated measure of ILD (11,28) to diagnose
ILD under blinded conditions. Third, patient followup
was a mean of 2 years. Finally, the size of our
SSc-related PH-ILD cohort was comparable with those
in a prior series by Le Pavec and colleagues (n  70) (6)
and a prior series by Condliffe and colleagues (n  56)
(4). The high percentage of ILD patients in the present
SSc-related PH cohort is likely a reflection of the
relatively large number of lung transplants performed at
our institution in patients with SSc-related ILD and the
high referral rate.
Our study has important limitations. The analysis
was limited to the data available and is subject to both
measurement and reporting bias. Moreover, inferences
cannot be made regarding causality.
Given the retrospective nature of this study,
systematic bias is possible, and patients who received
early prostanoid therapy may have had improved sur-
vival for reasons other than early prostanoid therapy.
Furthermore, the 3-year survival estimate should be
interpreted with caution given that the median followup
time per patient was 3 years. Type II errors may occur
in any inference test, particularly in retrospective stud-
ies. However, our finding of a P value of 0.01 for the
aggressive use of prostanoid in the multivariate model is
somewhat reassuring.
There is likely some selection bias. For example,
patients with SSc-related PH-ILD may have appeared
more ill at the time RHC was performed, prompting the
initiation of more aggressive PAH-targeted therapy. The
observation that patients who received early prostanoid
therapy were more likely to have ILD supports this
possibility. In addition, background PAH-targeted ther-
apy (i.e., type and onset of PDE-5 inhibitor or endothe-
lin receptor antagonist use) was not included as a
covariate in the multivariate model given variability in
the use and administration of these agents. Similarly, the
impact of type of prostanoid administered (i.e., paren-
teral versus oral versus inhaled) on survival was also not
explored in the present analysis due to the small num-
bers of patients receiving oral and inhaled prostanoid.
While survival in our cohort appears improved as
compared with historical series, this is a single-center
study and results may not be generalizable to other
populations. Finally, to adequately address the question
as to whether early aggressive PAH-targeted therapy
improves survival in SSc-related PH-ILD, one would
need a control population of SSc-related PH-ILD pa-
tients who were not receiving PAH therapy; this popu-
lation does not exist at our institution.
In conclusion, survival in patients with SSc-
related PH-ILD is historically poor and this may in part
be due to the fact that these patients are understudied in
clinical trials and likely undertreated for PH. Our expe-
rience suggests modestly improved survival rates in these
patients compared with patients in prior series. While
multiple factors may affect survival in patients with
SSc-related PH-ILD, early use of prostanoid therapy
was associated with improved survival in our cohort.
Future randomized controlled trials are needed to in-
vestigate outcomes associated with early use of prosta-
noid therapy in this vulnerable patient population.
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